Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate (VALIDGFR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Abdulfataah Mohamed, MSc
- Phone Number: +31503612955
- Email: a.a.a.mohamed@umcg.nl
Study Contact Backup
- Name: Secretariat Nephrology
Study Locations
-
-
-
Groningen, Netherlands, 9700 RB
- University Medical Centre Groningen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Scheduled to undergo a kidney function measurement test as part of standard care.
- Written informed consent.
Exclusion Criteria:
- History of hypersensitivity to iodinated contrast media or one of the excipients in the formulation of iohexol (trometamol, sodium calcium edetate, hydrochloric acid).
- Subjects with (suspected or known) thyrotoxicosis.
- Pregnant women and women of child-bearing potential who are not using reliable contraception.
- Patients who are unlikely to comply to the trial's procedure (non-compliance).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Iohexol in addition to 125I-iothalamate and 131I-hippuran
In this clinical trial, patients receiving 125I-iothalamate and 131I-hippuran during routine clinical care, will also receive iohexol.
This allows us to determine the mGFR using both methods in the same patient, and compare both methods in terms of accuracy and precision.
|
Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mGFR Iohexol
Time Frame: Through study completion, an average of 1 year
|
mGFR that is determined using the iohexol method
|
Through study completion, an average of 1 year
|
|
mGFR Iothalamate and hippuran
Time Frame: Through study completion, an average of 1 year
|
mGFR that is determined using the warm 125I-iothalamate and 131I-hippuran method
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repeated mGFR using iohexol on a separate study day
Time Frame: Through study completion, an average of 1 year
|
mGFR that is determined using the iohexol method
|
Through study completion, an average of 1 year
|
|
Repeated mGFR using iothalamate and hippuran on a separate study day
Time Frame: Through study completion, an average of 1 year
|
mGFR that is determined using the warm 125I-iothalamate and 131I-hippuran method
|
Through study completion, an average of 1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subgroup analysis mGFR
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on important patient characteristics.
This will be assessed per subgroup depending on the glomerular filtration rate (GFR) of the patients (patients with a mGFR: <30, 30-90, >90)
|
Through study completion, an average of 1 year
|
|
Subgroup analysis sex
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on the sex of the patient.
|
Through study completion, an average of 1 year
|
|
Subgroup analysis age
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on the age of the patient.
|
Through study completion, an average of 1 year
|
|
Subgroup analysis BMI
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on the BMI of the patient.
|
Through study completion, an average of 1 year
|
|
Subgroup analysis creatinine
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on the creatinine levels of the patient.
|
Through study completion, an average of 1 year
|
|
Subgroup analysis cystatin C
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on the cystatin C levels of the patient.
|
Through study completion, an average of 1 year
|
|
Subgroup analysis BSA
Time Frame: Through study completion, an average of 1 year
|
A subgroup analysis will be performed to assess whether precision and accuracy of the mGFR are dependent on the Body Surface Area (BSA) of the patient.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.